CLPBY:OTC-Coloplast A (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 13.68

Change

-0.05 (-0.36)%

Market Cap

USD 31.20B

Volume

8.72K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOY Essilor International SA

+0.23 (+0.20%)

USD 106.82B
ESLOF EssilorLuxottica Société ano..

+5.46 (+2.42%)

USD 104.69B
HOCPY Hoya Corp

-1.31 (-0.96%)

USD 46.93B
HOCPF HOYA Corporation

N/A

USD 46.92B
CLPBF Coloplast A/S

-5.71 (-4.15%)

USD 31.46B
TRUMF Terumo Corporation

-0.17 (-0.95%)

USD 29.47B
SAUHF Straumann Holding AG

+8.96 (+6.19%)

USD 23.15B
OCPNF Olympus Corporation

N/A

USD 20.54B
SRTOY Sartorius Stedim Biotech S.A

+0.24 (+1.15%)

USD 20.35B
SDMHF Sartorius Stedim Biotech S.A

+6.14 (+3.09%)

USD 20.03B

ETFs Containing CLPBY

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 18.65% 81% B- 72% C
Dividend Return 0.62% 32% F 9% A-
Total Return 19.27% 78% C+ 71% C-
Trailing 12 Months  
Capital Gain 24.82% 76% C+ 75% C
Dividend Return 2.78% 76% C+ 40% F
Total Return 27.60% 78% C+ 75% C
Trailing 5 Years  
Capital Gain 14.60% 58% F 68% D+
Dividend Return 11.80% 67% D+ 40% F
Total Return 26.40% 64% D 70% C-
Average Annual (5 Year Horizon)  
Capital Gain -1.61% 33% F 35% F
Dividend Return 0.44% 36% F 36% F
Total Return 2.05% 66% D+ 40% F
Risk Return Profile  
Volatility (Standard Deviation) 18.17% 91% A- 89% A-
Risk Adjusted Return 2.42% 37% F 36% F
Market Capitalization 31.20B 91% A- 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector